Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4936 USD | -4.34% | -2.51% | +31.63% |
Dec. 23 | CbdMD, Inc. Appoints T. Ronan Kennedy to Its Board of Directors | CI |
Dec. 18 | CbdMD, Inc., Q4 2024 Earnings Call, Dec 18, 2024 |
Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | 41.88M | 44.48M | 35.4M | 24.16M | 19.48M | ||
Total Revenues | 41.88M | 44.48M | 35.4M | 24.16M | 19.48M | ||
Cost of Goods Sold, Total | 15.51M | 14.5M | 13.07M | 9.18M | 7.49M | ||
Gross Profit | 26.37M | 29.99M | 22.34M | 14.98M | 12M | ||
Selling General & Admin Expenses, Total | 41.27M | 44.92M | 39.65M | 17.36M | 13.27M | ||
R&D Expenses | 1.16M | 1.42M | - | 173K | 39.02K | ||
Depreciation & Amortization - (IS) | - | 1.02M | - | 404K | 452K | ||
Amortization of Goodwill and Intangible Assets - (IS) | - | - | - | 1.4M | 698K | ||
Other Operating Expenses | 1.04M | 2.24M | - | 4.91M | 857K | ||
Other Operating Expenses, Total | 43.46M | 49.6M | 39.65M | 24.25M | 15.31M | ||
Operating Income | -17.09M | -19.62M | -17.31M | -9.27M | -3.32M | ||
Interest Expense, Total | - | -28.93K | - | - | -29.51K | ||
Interest And Investment Income | 39.88K | - | - | 63.7K | - | ||
Net Interest Expenses | 39.88K | -28.93K | - | 63.7K | -29.51K | ||
Other Non Operating Income (Expenses) | -1 | 29.48K | 255K | - | - | ||
EBT, Excl. Unusual Items | -17.05M | -19.62M | -17.06M | -9.2M | -3.34M | ||
Restructuring Charges | - | - | -602K | - | - | ||
Impairment of Goodwill | - | - | -60.96M | - | - | ||
Gain (Loss) On Sale Of Investments | -932K | 547K | -33.35K | -700K | - | ||
Gain (Loss) On Sale Of Assets | - | - | 88.77K | - | - | ||
Asset Writedown | - | - | - | -13.22M | - | ||
Other Unusual Items | 29.29M | -5.22M | 8.47M | 186K | -355K | ||
EBT, Incl. Unusual Items | 11.31M | -24.29M | -70.08M | -22.94M | -3.7M | ||
Income Tax Expense | -1.35M | -895K | - | - | - | ||
Earnings From Continuing Operations | 12.65M | -23.39M | -70.08M | -22.94M | -3.7M | ||
Earnings Of Discontinued Operations | -48.98K | - | - | - | - | ||
Net Income to Company | 12.6M | -23.39M | -70.08M | -22.94M | -3.7M | ||
Minority Interest | - | - | - | - | - | ||
Net Income - (IS) | 12.6M | -23.39M | -70.08M | -22.94M | -3.7M | ||
Preferred Dividend and Other Adjustments | 367K | 2.55M | 4M | 4M | 4M | ||
Net Income to Common Incl Extra Items | 12.24M | -25.95M | -74.09M | -26.94M | -7.7M | ||
Net Income to Common Excl. Extra Items | 12.28M | -25.95M | -74.09M | -26.94M | -7.7M | ||
Per Share Items | |||||||
Net EPS - Basic | 12.47 | -21.26 | -55.8 | -13.32 | -1.79 | ||
Basic EPS - Continuing Operations | 12.52 | -21.26 | -55.8 | -13.32 | -1.79 | ||
Basic Weighted Average Shares Outstanding | 981K | 1.22M | 1.33M | 2.02M | 4.31M | ||
Net EPS - Diluted | 12.47 | -21.26 | -55.8 | -13.32 | -1.79 | ||
Diluted EPS - Continuing Operations | 12.52 | -21.26 | -55.8 | -13.32 | -1.79 | ||
Diluted Weighted Average Shares Outstanding | 1M | 1.22M | 1.33M | 2.02M | 4.31M | ||
Normalized Basic EPS | -10.87 | -10.04 | -8.03 | -2.84 | -0.48 | ||
Normalized Diluted EPS | -10.62 | -10.04 | -8.03 | -2.84 | -0.48 | ||
Payout Ratio | 2.91 | -10.92 | -5.71 | -15.99 | - | ||
Supplemental Items | |||||||
EBITDA | -16.37M | -18.6M | -15.48M | -7.47M | -2.17M | ||
EBITA | -17.09M | -19.57M | -16.43M | -7.87M | -2.62M | ||
EBIT | -17.09M | -19.62M | -17.31M | -9.27M | -3.32M | ||
EBITDAR | -14.83M | -17.05M | -14.09M | -6.14M | 512K | ||
Total Revenues (As Reported) | 41.88M | 44.48M | 35.4M | 24.16M | 19.48M | ||
Effective Tax Rate - (Ratio) | -11.9 | 3.68 | - | - | - | ||
Deferred Domestic Taxes | -1.35M | -895K | - | - | - | ||
Total Deferred Taxes | -1.35M | -895K | - | - | - | ||
Normalized Net Income | -10.66M | -12.26M | -10.66M | -5.75M | -2.09M | ||
Supplemental Operating Expense Items | |||||||
Advertising Expense | - | - | - | - | - | ||
Marketing Expenses | 14.92M | 17.9M | 15.36M | 5.98M | 4.18M | ||
Selling and Marketing Expenses | 16.82M | 19.64M | - | 6.95M | 4.18M | ||
General and Administrative Expenses | 5.11M | 4.36M | - | 2.62M | 2.17M | ||
Research And Development Expense From Footnotes | 1.16M | 1.42M | - | 173K | 39.02K | ||
Net Rental Expense, Total | 1.54M | 1.55M | 1.39M | 1.33M | 2.68M | ||
Imputed Operating Lease Interest Expense | - | 48.54K | - | - | 255K | ||
Imputed Operating Lease Depreciation | - | 1.5M | - | - | 2.42M | ||
Stock-Based Comp., SG&A Exp. (Total) | 1.99M | 3.15M | - | 349K | 43.69K | ||
Stock-Based Comp., Other (Total) | 391K | 97.72K | - | 885K | - | ||
Total Stock-Based Compensation | 2.38M | 3.25M | - | 1.23M | 43.69K |